Episode 2: Other COVID-19 Vaccine Platforms

Listen on: Apple Amazon Spotify Podbean Audible and others

Adenovirus image by Dr. Richard Feldmann at the National Cancer Institute

This is the original Pathogen Perspectives episode rebranded for Infectious Dose.

In this episode, Heather provides an in-depth discussion on the COVID-19 vaccine platforms other than mRNA, currently in clinical trials around the world. These include self-replicating mRNA, DNA, Protein-based, Attenuated virus, Inactivated virus, Repurposed vaccines, and virus vector vaccines. Heather discusses what each platform is, their pros and cons, and let's you know about those with current emergency use authorization.

· What each platform involves

· Pros and cons

· Those of each type currently authorized for emergency use

· Unexpected introduction to salty Heather after a rough week.

Relevant links

Episode 2 Transcript PDF

https://covid19.trackvaccines.org/

Pathogen Perspectives the Blog

NYT Coronavirus Vaccine Tracker

Use of adenovirus type-5 vectored vaccines: a cautionary tale by Susan P Buchbinder, M Juliana McElrath, Carl Dieffenbach, and Lawrence Corey

Cohen, J. 2007. AIDS research. Did Merck's failed HIV vaccine cause harm? Science. 318:1048–1049.

Ledford, H. 2007. HIV vaccine may raise risk. Nature. 450:325.

Merck's HIV vaccine flop brings vectors under closer scrutiny. Ledford H. Nat Biotechnol. 2008 Jan;26(1):3-4. Behind paywall so here you go:

Merck's HIV vaccine flop brings vectors under closer scrutiny.pdf

Download PDF • 486KB

Cohen, J. 2007. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science. 318:28–29.

HIV vaccine failure prompts Merck to halt trial

Historical Perspective of Rabies in Europe and the Mediterranean Basin, A testament to rabies by Dr Arthur A. King